The ET market is advancing through enhanced diagnostic precision and novel therapeutic approaches. Industry leaders including Novartis, Incyte, and PharmaEssentia are pioneering next-generation JAK inhibitors and targeted treatments that improve platelet control and reduce thrombotic complications. Evolving treatment guidelines and molecular monitoring are enabling more personalized patient management strategies.
Access Market Analysis: https://shorturl.at/QyAgR
Comment
Share
